Q3 2023 Earnings

November 2023





This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like "expects," "estimates," "anticipates," "may," "could," "believes," "feels," "plans," "intends" or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec's Annual Report on Form 10-K for the year ended December 31, 2022, Innospec's Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors" in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



The information presented in this presentation includes financial measures that are not calculated or presented in accordance with Generally Accepted Accounting Principles in the United States (GAAP). These non-GAAP financial measures comprise EBITDA, income before income taxes excluding special items, net income excluding special items and related per share amounts together with net cash. EBITDA is net income per our consolidated financial statements adjusted for the exclusion of charges for interest expense, net, income taxes, depreciation and amortization. Income before income taxes, net income and diluted EPS, excluding special items, per our consolidated financial statements are adjusted for the exclusion of foreign currency exchange (gains)/losses, amortization of acquired intangible assets, legacy costs of closed operations, acquisition related costs and adjustment of income tax provisions. Net cash is cash and cash equivalents less total debt. The Company believes that such non-GAAP financial measures provide useful information to investors and may assist them in evaluating the Company's underlying performance and identifying operating trends. In addition, these non-GAAP measures address questions the Company routinely receives from analysts and investors and the Company has determined that it is appropriate to make this data available to all investors. While the Company believes that such measures are useful in evaluating the Company's performance, investors should not consider them to be a substitute for financial measures prepared in accordance with GAAP. Also, these non-GAAP financial measures may differ from similarly-titled non-GAAP financial measures used by other companies and do not provide a comparable view of the Company's performance relative to other companies in similar industries. Management uses adjusted EPS (the most directly comparable GAAP financial measure for which is GAAP EPS) and adjusted net income and EBITDA (the most directly comparable GAAP financial measure for which is GAAP net income) to allocate resources and evaluate the performance of the Company's operations. Management believes the most directly comparable GAAP financial measure is GAAP net income and has provided a reconciliation of EBITDA and net income excluding special items, and related per share amounts, to GAAP net income in our earnings release.



- 1 Introduction David Jones - VP, General Counsel
- 2 Business Commentary Patrick S. Williams - President & CEO
- 3 Financial Performance Ian Cleminson - Executive Vice President & CFO
- 4 Questions & Answers Patrick S. Williams and Ian Cleminson





GAAP EPS of \$1.57

Adjusted non-GAAP EPS of \$1.59

Semi-annual dividend increased to 72 cents per share

Full year dividend up 10 percent to \$1.41

Excellent \$58.1 million cash from operations in the quarter

Strong balance sheet has \$207.2 million in net cash

Performance Chemicals strong sequential improvement in operating income and margins

Volume improvement

Fuel Specialties consistent performance with improved margins Oilfield Services continued excellent results

©2023 Innospec Inc.

Financial Performance



Q3 2023 Consolidated Results (\$ MM)

innospec





Gross margin down 0.8
 percentage points

Operating income down 16
 percent


• EBITDA down 5 percent




Q3 2023 Performance Chemicals (\$ MM)

24.5%

innospec





- Sales down 9 percentPrice/mix down 19 percent
 - Volumes up 7 percent


\$21.3

- Gross margin down 3.6
 percentage points
- Operating income down 33
 percent



Q3 2023 Fuel Specialties (\$ MM)

innospec



Sales down 5 percent

• Price/mix down 4 percent


• Volumes down 4 percent

• Gross margin up 1.4 percentage points

 Operating income similar to prior year

innospec






\$19.5

- Sales down 14 percent
- Gross margin down 0.4
 percentage points
- Operating income up 15
 percent








Corporate Costs

Effective Tax Rate




• Effective tax rate of 17.5 percent



Q3 2023 Balance Sheet (\$ MM)

innospec



- Excellent operating cash inflow of \$58.1 million
- Capital expenditures of \$16.7 million
- Strong net cash balance of \$207.2 million

Concluding Comments





Summary of 3rd Quarter Performance

Entering fourth quarter with good momentum in all businesses

Continued benefits from balanced portfolio

Consumer and regulatory trends driving organic growth opportunities

Flexible, debt-free balance sheet; Consistent shareholder returns

Semi-annual dividend increased to 72 cents per share; Annual dividend now \$1.41, up 10 percent annually

\$207.2 million net cash on balance sheet to pursue organic growth and M&A



©2023 Innospec Inc.



Final Comments

Thank You for Your Continued Support

February 2024						
Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29		

Q4 2023 Results Schedule

- February 13th Results Release After Close
- February 14th Conference Call